Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fibre infection model (HFIM)

Zahra Sadouki, Emmanuel Q. Wey, Sateesh Iype, David Nasralla, Jonathan Potts, Mike Spiro, Alan Williams, Timothy D. McHugh, View ORCID ProfileFrank Kloprogge
doi: https://doi.org/10.1101/2024.04.08.24301402
Zahra Sadouki
1Institute for Global Health, University College London, UK
2Centre of Clinical Microbiology, University College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Q. Wey
2Centre of Clinical Microbiology, University College London, UK
3Department of Infection, Royal Free London NHS Trust, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emmanuel.wey{at}nhs.net
Sateesh Iype
4Department of HPB and Liver Transplant Surgery Royal Free Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Nasralla
4Department of HPB and Liver Transplant Surgery Royal Free Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Potts
5Department of Hepatology, Sheila Sherlock Liver Unit, Royal Free London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Spiro
6Department of Surgical biotechnology, UCL
7Department of Intensive care medicine Royal Free London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Williams
8Department of Infection Sciences, Health Services Laboratories, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy D. McHugh
2Centre of Clinical Microbiology, University College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Kloprogge
1Institute for Global Health, University College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frank Kloprogge
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background & aims An extensively-drug resistant (XDR) NDM and OXA-48 producing E. coli contributing to repeat episodes of biliary sepsis was isolated from the blood stream of a 45-55 year-old male with a background of IgG4 related sclerosing cholangitis. The patient was awaiting orthotopic liver transplant (OLT). There is no standardized antibiotic prophylaxis regimen however in line with the Infectious Diseases Society of America (IDSA) guidance an antibiotic prophylactic regimen of Ceftazidime-Avibactam (CZA) 2.5g TDS with Aztreonam (ATM) 2g TDS IV was proposed.

Methods To inform the individualised pharmacodynamic outcome likelihood prior to prophylaxis dosing the hollow fibre infection model (HFIM) was applied to simulate the in vivo antibiotic exposures of the CZA-ATM regimen. The HFIM was inoculated with ∼10 x 105 bacterial CFU/mL of the XDR E. coli strain and CFUs/mL were measured for a total of 120 hours to determine the in vitro PK/PD killing dynamics.

Results A 4-log reduction in CFU/mL in the first ten hours of the regimen exposure was observed however the killing dynamics were slow and six eight-hourly infusions were required to reduce bacterial cells to below the limit of quantification. Thus, the HFIM supported the use of the regimen for infection clearance however highlighted the need for several infusions. Standard local practise is to administer prophylaxis antibiotics at induction of OLT however the HFIM provided data to rationalise earlier dosing therefore the patient was dosed at 24 hours prior to their OLT induction. The patient was subsequently discharged 8 days after surgery.

Conclusions The HFIM provides a dynamic culture solution for informing individualised medicine by testing antibiotic combinations and exposures against the bacterial isolates cultured from the patient’s infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was conducted as part of Z.S. PhD studentship that was partially funded by an educational grant from Shionogi B.V. and by University College London. FK has been recipient of a UKRI Medical Research Council Skills Development Fellowship MR/P014534/1, and a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number 220587/Z/20/Z).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Health Research Authority Decision Panel advisors did not consider the work research but a deviation from standard of care that was purely for clinical needs. Review by an NHS Research Ethics Committee was therefore not required.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Conflict of interest statement: No conflicts of interest.

  • Financial support statement: This work was conducted as part of Z.S.’s PhD studentship that was partially funded by an educational grant from Shionogi B.V. and by University College London. FK has been recipient of a UKRI Medical Research Council Skills Development Fellowship MR/P014534/1, and a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number 220587/Z/20/Z).

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 12, 2024.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fibre infection model (HFIM)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fibre infection model (HFIM)
Zahra Sadouki, Emmanuel Q. Wey, Sateesh Iype, David Nasralla, Jonathan Potts, Mike Spiro, Alan Williams, Timothy D. McHugh, Frank Kloprogge
medRxiv 2024.04.08.24301402; doi: https://doi.org/10.1101/2024.04.08.24301402
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fibre infection model (HFIM)
Zahra Sadouki, Emmanuel Q. Wey, Sateesh Iype, David Nasralla, Jonathan Potts, Mike Spiro, Alan Williams, Timothy D. McHugh, Frank Kloprogge
medRxiv 2024.04.08.24301402; doi: https://doi.org/10.1101/2024.04.08.24301402

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)